- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Allogene Therapeutics announced the activation of clinical trials across the U.S. and Canada, aligning with the FDA on pivotal trial design.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Allogene Therapeutics announced the activation of clinical trials across the U.S. and Canada, aligning with the FDA on pivotal trial design.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Allogene Therapeutics is seeking designations for its cema-cel therapy and expanding its clinical trials internationally, including the ALPHA3 trial.Sub-event
Allogene Therapeutics advanced its clinical trials and secured alignment with the FDA on pivotal trial design.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
Allogene Therapeutics (United States)
company in San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireAllogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in La